Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?

Cancer Med. 2016 Jul;5(7):1542-5. doi: 10.1002/cam4.699. Epub 2016 Mar 31.

Abstract

The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low-grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan-bevacizumab followed by a metronomic maintenance with weekly vinblastine to try to prevent relapses. After a median follow-up of 23 months after the end of the bevacizumab-irinotecan induction, no patient relapsed. These observations suggest that maintenance chemotherapy with weekly vinblastine after an induction by irinotecan-bevacizumab can improve progression-free survival in children with LGG.

Keywords: Angiogenesis; cancer; children; low-grade glioma; malignancies metronomic chemotherapy.

MeSH terms

  • Administration, Metronomic
  • Adolescent
  • Antineoplastic Agents, Phytogenic / administration & dosage*
  • Antineoplastic Agents, Phytogenic / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab / administration & dosage
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Child
  • Combined Modality Therapy
  • Disease Progression
  • Female
  • Glioma / diagnostic imaging
  • Glioma / drug therapy*
  • Glioma / pathology*
  • Humans
  • Irinotecan
  • Maintenance Chemotherapy
  • Male
  • Neoplasm Grading
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local
  • Retreatment
  • Retrospective Studies
  • Vinblastine / administration & dosage*
  • Vinblastine / adverse effects

Substances

  • Antineoplastic Agents, Phytogenic
  • Bevacizumab
  • Vinblastine
  • Irinotecan
  • Camptothecin